| Abstract | Cite as


Substantive changes at this update

Anticholinergics New evidence added.[21][22][23][24] Categorisation unchanged (Beneficial).

Beta2 agonists (inhaled) New evidence added.[28][32][37][38][39][40][41] Categorisation unchanged (Beneficial).

Theophylline New evidence added.[50][51] Categorisation unchanged (Trade-off between benefits and harms).

Corticosteroids (inhaled) New evidence added.[58][61][62] Categorisation unchanged (Beneficial).

Corticosteroids plus long-acting beta2 agonists New evidence added.[65][66][67][68][70] Categorisation unchanged (Beneficial).

Mucolytics New evidence added.[74] Categorisation unchanged (Unknown effectiveness) as all the RCTs we found had methodological flaws.

Antibiotics (prophylactic) New evidence added.[77] Categorisation unchanged (Unknown effectiveness) as the evidence is contradictory and much comes from trials completed before 1970.

Alpha1 antitrypsin New evidence added.[81] Categorisation unchanged (Unknown effectiveness) as there remains insufficient evidence to judge this intervention.

Pulmonary rehabilitation New evidence added.[100][101][102][103][104][105] Categorisation unchanged (Beneficial).

Inspiratory muscle training New evidence added.[108] Categorisation unchanged (Likely to be beneficial).

Peripheral muscle strength training (alone) New evidence added.[109] Categorisation unchanged (Likely to be beneficial).

General physical activity enhancement (alone) New evidence added.[113] Categorisation unchanged (Likely to be beneficial).


INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a disease state characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. Classically, it is thought to be a combination of emphysema and chronic bronchitis, although only one of these may be present in some people with COPD. The main risk factor for the development and deterioration of COPD is smoking. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of maintenance drug treatment in stable COPD? What are the effects of smoking cessation interventions in people with stable COPD? What are the effects of non-drug interventions in people with stable COPD? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 119 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: alpha1 antitrypsin, antibiotics (prophylactic), anticholinergics (inhaled), beta2 agonists (inhaled), corticosteroids (oral and inhaled), general physical activity enhancement, inspiratory muscle training, nutritional supplementation, mucolytics, oxygen treatment (long-term domiciliary treatment), peripheral muscle strength training, psychosocial and pharmacological interventions for smoking cessation, pulmonary rehabilitation, and theophylline.

Cite as

McIvor RA, Tunks M, Todd DC. COPD. Systematic review 1502. BMJ Clinical Evidence. . 2011 June. Accessed [date].

Latest citations

Danish register-based study on the association between specific antipsychotic drugs and fractures in elderly individuals. ( 10 January 2017 )

Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. ( 10 January 2017 )